NCT00111631View on ClinicalTrials.gov

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

DPP-IV Inhibitor

Escalating doses po bid

DRUG

Metformin

As prescribed

DRUG

Placebo

po bid

Trial Locations (37)

2050

Sydney

5000

Adelaide

10115

Berlin

14209

Buffalo

14609

Rochester

15425

Connellsville

18974

Warminster

19085

Wilmington

19713

Newark

27713

Durham

33100

Udine

33156

Miami

33765

Clearwater

37431

Bad Lauterberg im Harz

41460

Neuss

44260

Mogadore

50100

Florence

55116

Mainz

60131

Ancona

60607

Chicago

75246

Dallas

78229

San Antonio

79707

Midland

80100

Napoli

80304

Boulder

92161

San Diego

93901

Salinas

94520

Concord

97239

Portland

48202-2689

Detroit

R3E 3P4

Winnipeg

B3H 1V7

Halifax

NGA 4V2

London

M5C 2T2

Toronto

01307

Dresden

02826

Görlitz

00716

Ponce

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00111631 - A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter